GREAT NECK, N.Y.--(BUSINESS WIRE)--Neogenix Oncology, Inc. (Neogenix) announced today that the Johns Hopkins Hospital has initiated a Phase I trial with the company’s first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.
